Register to receive a free U.S. Market Report Suite for Diagnostic Ophthalmic Devices – MedSuite report synopsis and brochure
Avinger, Inc., a leading developer of innovative treatments for peripheral artery disease (PAD), announced the issuance of an important new patent covering the Company’s Pantheris image-guided atherectomy system.
The U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 10,052,125, titled “Atherectomy Catheter With Laterally-Displaceable Tip,” on August 21, 2018. This is the fifth patent issued by the USPTO with claims related to Avinger’s Pantheris image-guided atherectomy system. The patent describes an atherectomy catheter (which is a device used to remove plaque from blood vessels) including real-time image guidance using optical coherence tomography (OCT), a displaceable tip and a balloon to urge the catheter’s cutting element into the tissue to be removed. These are all key features of the Pantheris atherectomy system. The next-generation version of this system was cleared by the FDA for commercial sale in the U.S. in May 2018. Pantheris is the only commercially available atherectomy device with on-board intravascular image-guidance.
“The issuance of this patent by the USPTO is an important milestone in Avinger’s development of image-guided devices for the treatment of PAD,” commented Himanshu Patel, Avinger’s co-founder and Chief Technology Officer. “Our extensive patent portfolio is an important source of competitive advantage as more and more physicians recognize the value of our Lumivascular technology in obtaining the best clinical outcomes for their patients.”
Avinger’s extensive intellectual property portfolio now includes 131 patents and applications, including 21 issued and allowed U.S. cases, 26 pending U.S. applications, 37 issued and allowed cases outside the U.S., and 47 pending applications outside the U.S. The portfolio has broad applicability in the areas of atherectomy, CTO-crossing and intravascular imaging.
About Avinger, Inc.
Avinger is a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, CA.
For Further Information
More on the interventional ophthalmic market in the U.S can be found in a series of reports published by iData Research entitled the U.S. Market Report Suite for Diagnostic Ophthalmic Devices. The suite covers reports on the following markets: ophthalmic coherence tomography, fundus cameras, data management systems, slit lamps, perimeters, tonometers, autorefractors/keratometers, binocular indirect ophthalmoscopes, ophthalmic ultrasound devices, wavefront abberometers, corneal topographers, and optical biometers.
The iData report series on ophthalmic devices covers the U.S. and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about ophthalmic device market data, register online or email us at email@example.com for a U.S. Market Report Suite for Diagnostic Ophthalmic Devices brochure and synopsis.